Indivior Pharmaceuticals Inc (INDV) 의 후행 P/E는 19.1, 선행 P/E 10.4. 후행 이익수익률은 5.23%, 선행 이익수익률 9.60%. PEG 0.12 (Peter Lynch 저평가 ≤1.0).
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 72/100 5/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 79.7 | 0.00 | -8.66 | 2.64 | 2.47% |
| 2017 | 65.1 | 0.72 | -19.54 | 3.45 | - |
| 2018 | 3.7 | 0.01 | 14.87 | 1.02 | - |
| 2019 | 2.8 | -0.06 | 1.82 | 0.48 | - |
| 2020 | -7.3 | 0.03 | 13.14 | 1.67 | - |
| 2021 | 12.3 | -0.05 | 12.38 | 3.18 | - |
| 2022 | -68.7 | 0.54 | 58.97 | 3.36 | - |
| 2023 | -16.5 | 0.16 | -11.12 | 1.94 | - |
| 2024 | 820.4 | 239.55 | -4.71 | 1.38 | - |
| 2025 | 21.4 | 0.00 | -45.77 | 3.62 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $0.22 | $968.89M | $32.05M | 3.3% |
| 2017 | $0.41 | $1.15B | $60.92M | 5.3% |
| 2018 | $1.75 | $959.92M | $262.67M | 27.4% |
| 2019 | $0.92 | $815.16M | $139.15M | 17.1% |
| 2020 | $-1.08 | $689.68M | $-157.76M | -22.9% |
| 2021 | $1.31 | $777.48M | $205M | 26.4% |
| 2022 | $-0.37 | $884.63M | $-52.04M | -5.9% |
| 2023 | $0.01 | $1.09B | $2M | 0.2% |
| 2024 | $0.02 | $1.19B | $2M | 0.2% |
| 2025 | $1.64 | $1.24B | $210M | 16.9% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $3.12 | $2.69 – $3.38 | $1.16B | $1.13B – $1.19B | 4 |
| 2027 | $3.44 | $3.13 – $3.79 | $1.22B | $1.2B – $1.26B | 4 |
| 2028 | $3.81 | $3.68 – $3.97 | $1.3B | $1.27B – $1.34B | 1 |
| 2029 | $3.84 | $3.71 – $4.00 | $1.36B | $1.33B – $1.4B | 1 |
| 2030 | $4.15 | $4.01 – $4.32 | $1.38B | $1.34B – $1.42B | 1 |
